BACE2

(redirected from Drap)
Also found in: Dictionary, Acronyms, Wikipedia.

BACE2

A gene on chromosome 21q22.3 that encodes beta secretase 2, a transmembrane enzyme responsible for the proteolysis of the amyloid precursor protein, leading to the generation and extracellular release of beta-cleaved soluble AP. It is expressed at low levels in most peripheral tissues and at higher levels in the colon, kidney, pancreas, placenta, prostate (in benign and malignant ducts), stomach and trachea.
References in periodicals archive ?
He said that the resultant approaches for regulation of therapeutic goods including medical devices, Health and OTC products, and Pharmaceutical and Biological drugs contributed towards the overall increase in the efficiency of the authority, that is evident from the recently published reports of WHO and USP PQM determining DRAP as the fastest growing regulatory authority in the region.
Due to efforts by Drap and the provincial authorities, the number of spurious drugs on the market has dropped in 2017 and drug courts have imposed fines worth Rs32 million in various cases, the statement says.
In this regard DRAP intends to initiate all activities against spurious, unregistered and sub-standard medicines in consultation with the provincial health departments.
Due to the activities of the DRAP and provinces the percentage of spurious drugs has dropped in 2017.
Anyone who takes any action against DRAP without the Supreme Court's permission will not be pardoned," he said.
The minister said that campaigns against spurious drugs and fake drugs are conducted regularly and DRAP has initiated the process of World Health Organization (WHO) pre-qualification of CDL, Karachi to strengthen the quality control of drugs used in the country.
This initiative has been developed and successfully launched by the new dedicated MIS team of DRAP, timely fulfilling their commitment, in the larger interest of patients.
The Supreme Court in hearing of the case on March 20, 2014, fixed case of un-authorized price increase by the pharmaceutical companies for 3rd week of April, 2014 and directed DRAP to submit a comprehensive report on the matter.
CEO, DRAP briefed the members regarding all the actions taken against M/s.
The CJP remarked ' How the NAB dared to interfere and issue notice to DRAP despite being the matter sub judice.
Spokesperson for Drap Sajid Hussain Shah told Dawn that the decision to cancel the licence was taken at a meeting of the licensing board chaired by Ghulam Sarwar Dotani.
A Supreme Court bench was hearing a human rights application filed by Drap against the company for producing unregistered drugs.